NEW YORK — Grail, a developer of early cancer detection technologies, on Wednesday filed with the US Securities and Exchange Commission to go public on the Nasdaq.
The Menlo Park, California-based company did not specify the number of shares it intends to float or a price range for the proposed initial public offering. Morgan Stanley, Goldman Sachs, and BofA Securities will act as lead bookrunners of the offering.